Cited by 802Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchCancer Genomics and Diagnostics

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Intragenic ERBB2 kinase mutations in tumours

Stephens, Philip, Hunter, Chris, Bignell, Graham, Edkins, Sarah, Davies, Helen, Teague, Jon, Stevens, Claire, O'Meara, Sarah, Smith, Raffaella, Parker, Adrian, Barthorpe, Andy, Blow, Matthew, Brackenbury, Lisa, Butler, Adam, Clarke, Oliver, Cole, Jennifer, Dicks, Ed, Dike, Angus, Drozd, Anja, Edwards, Ken, Forbes, Simon, Foster, Rebecca, Gray, Kristian, Greenman, Chris, Halliday, Kelly, Hills, Katy, Kosmidou, Vivienne, Lugg, Richard, Menzies, Andy, Perry, Janet, Petty, Robert, Raine, Keiran, Ratford, Lewis, Shepherd, Rebecca, Small, Alexandra, Stephens, Yvonne, Tofts, Calli, Varian, Jennifer, West, Sofie, Widaa, Sara, Yates, Andrew, Brasseur, Francis, Cooper, Colin S., Flanagan, Adrienne M., Knowles, Margaret, Leung, Suet Y., Louis, David N., Looijenga, Leendert H. J., Malkowicz, Bruce, Pierotti, Marco A., Teh, Bin, Chenevix-Trench, Georgia, Weber, Barbara L., Yuen, Siu T., Harris, Grace, Goldstraw, Peter, Nicholson, Andrew G., Futreal, P. Andrew, Wooster, Richard, Stratton, Michael R.·2004·Nature

DOI 10.1038/431525b

Open this paper in CoChat — free account

Abstract

The protein-kinase family is the most frequently mutated gene family found in human cancer and faulty kinase enzymes are being investigated as promising targets for the design of antitumour therapies. We have sequenced the gene encoding the transmembrane protein tyrosine kinase ERBB2 (also known as HER2 or Neu) from 120 primary lung tumours and identified 4% that have mutations within the kinase domain; in the adenocarcinoma subtype of lung cancer, 10% of cases had mutations. ERBB2 inhibitors, which have so far proved to be ineffective in treating lung cancer, should now be clinically re-evaluated in the specific subset of patients with lung cancer whose tumours carry ERBB2 mutations.

Integrity signals

Registry

Crossref · 10.1038/431525b

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Self-citation
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
A census of human cancer genes
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184
Self-citation
Opportunities and challenges in the development of kinase inhibitor therapy for cancerPreprint
Sawyers, C. L. (2003) · Genes & Development · doi:10.1101/gad.1152403 · Cited by 170
The role of HER2/neu expression and trastuzumab in non-small cell lung cancer
Hirsch, F. R., & Langer, C. J. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.12.018 · Cited by 64
Toward Customized Trastuzumab in HER-2/neu-Overexpressing Non-Small-Cell Lung Cancers
Rosell, R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.904 · Cited by 30

Flagged first, then by citations

Show all 7 references

Research works printed but not linked: 1

Klapper, S. et al. Adv. Cancer Res. 1, 25–79 (2000).

Sorted by citations

Items 501–600 of 802

Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
Morris, S. R., & Carey, L. (2006) · PubMed · Cited by 15
Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer
Dancey, J. E. (2007) · Drugs · doi:10.2165/00003495-200767080-00003 · Cited by 15
The Use of Chemical-Chemical Interaction and Chemical Structure to Identify New Candidate Chemicals Related to Lung Cancer
Chen, L., Yang, J., Zheng, M., Kong, X., Huang, T., & Cai, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128696 · Cited by 14
“The NSCLCs are divided into three subtypes: adenocarcinoma, squamous-cell carcinoma and large-cell carcinoma.”
Background
ERBB2 juxtamembrane domain (trastuzumab binding site) gene mutation is a rare event in invasive breast cancers overexpressing the ERBB2 gene
Khoury, T., Mojica, W. D., Hicks, D. G., Starostik, P., Ademuyiwa, F. O., Janarthanan, B., & Cheney, R. T. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.64 · Cited by 14
Transforming science: cancer gene identification
Collier, L. S., & Largaespada, D. A. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2005.11.001 · Cited by 14
The rapidly changing field of predictive biomarkers of non-small cell lung cancer
Tóth, L. J., Mokánszki, A., & Méhes, G. (2024) · Pathology & Oncology Research · doi:10.3389/pore.2024.1611733 · Cited by 15
Specific HER2 Exon 20 Gly776 Deletion-Insertions in Non-Small Cell Lung Cancer: Structural Analysis and Sensitivity to HER2-Targeted Tyrosine Kinase Inhibitors
Yang, G., Xu, H., Hu, J., Liu, R., Hu, P., Yang, Y., Li, W., Hao, X., Zhang, S., Xu, F., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.806737 · Cited by 13
Antibody–Drug Conjugates in Non-Small Cell Lung Cancer: Emergence of a Novel Therapeutic Class
Marks, J. A., Wilgucki, M., Liu, S. V., & Reuss, J. E. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01334-9 · Cited by 13
ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma
Hutchinson, K. E., Johnson, D. B., Johnson, A. S., Sanchez, V. M., Kuba, M. G., Wang, L., Chen, X., Kelley, M. C., Wang, Q., Zhao, Z., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4255 · Cited by 13
Proteomics revisits the cancer metabolome
Hu, H., Deng, C., Yang, T., Dong, Q. G., Chen, Y., Nice, E. C., Huang, C., & Wei, Y. (2011) · Expert Review of Proteomics · doi:10.1586/epr.11.31 · Cited by 13
Novel strategies to augment genetically delivered immunotoxin molecular therapy for cancer therapy
Liu, X., Wu, J., Zhang, S., Li, C., & Huang, Q. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.30 · Cited by 13
Induction of Apoptosis by PQ1, a Gap Junction Enhancer that Upregulates Connexin 43 and Activates the MAPK Signaling Pathway in Mammary Carcinoma Cells
Shishido, S. N., & Nguyen, T. A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020178 · Cited by 13
“Aberrant overexpression or mutational activation of receptor tyrosine kinases can cause hyperactivation of Ras leading to upregulated MAPK signaling [32–34].”
Background
pathCHEMO, a generalizable computational framework uncovers molecular pathways of chemoresistance in lung adenocarcinoma
Epsi, N. J., Panja, S., Pine, S. R., & Mitrofanova, A. (2019) · Communications Biology · doi:10.1038/s42003-019-0572-6 · Cited by 13
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study
Ganti, A. K., Rothe, M., Mangat, P. K., Garrett-Mayer, E. S., Dib, E. G., Duvivier, H. L., Ahn, E. R., Behl, D., Borghaei, H., Balmanoukian, A. S., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00041 · Cited by 13
MicroRNA-361-5p suppresses cancer progression by targeting signal transducer and activator of transcription 6 in non-small cell lung cancer
Ma, Y., Bao, C., Kong, R., Xing, X., Zhang, Y., Li, S., Zhang, W., Jiang, J., Zhang, J., Qiao, Z., et al. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.4411 · Cited by 13
Epithelial ovarian cancer stem-like cells expressing α-gal epitopes increase the immunogenicity of tumor associated antigens
Yao, X., Dong, Z., Zhang, Q., Wang, Q., & Lai, D. (2015) · BMC Cancer · doi:10.1186/s12885-015-1973-7 · Cited by 13
“Mass spectrometric analysis demonstrated that the protein reacted with the new Abs including a protein c-erbB-2, which was associated with poor prognosis in cancers such as salivary gland adenocarcinoma, breast cancer, and lung cancer [42–44].”
Background
Classic Anatomic Pathology and Lung Cancer
Wistuba, I. I., Brambilla, E. M., & Noguchi, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52357-8.00017-2 · Cited by 13
3D in vitro models of tumors expressing EGFR family receptors: a potent tool for studying receptor biology and targeted drug development
Соколова, Е. А., Vodeneev, V., Deyev, S. M., & Владимировна, Б. И. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.09.003 · Cited by 13
Comparative analysis of co-occurring mutations of specific tumor suppressor genes in lung adenocarcinoma between Asian and Caucasian populations
Zhang, Y., Ma, Y., Li, Y., Shen, X., Yu, Y., Pan, Y., Zhang, Y., Zheng, D., Zhao, Y., Ye, T., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-02828-5 · Cited by 13
Construction and Deciphering of Human Phosphorylation-Mediated Signaling Transduction Networks
Zhang, M., Li, H., He, Y., Sun, H., Li, X., Wang, L., Sun, B., Ma, L., Zhang, G., Li, J., et al. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00249 · Cited by 13
Molecular Carcinogenesis
Zachariadis, M., Evangelou, K., Kastrinakis, N. G., Papanagnou, P., & Gorgoulis, V. G. (2010) · Springer eBooks · doi:10.1007/978-3-540-71915-1_74 · Cited by 13
Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs
Nilsson, M. B., Le, X., Poteete, A., Yu, X., He, J., Huang, Q., Shibata, Y., Liu, X., Moran, C., Alizadeh, A. A., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.01.007 · Cited by 14
A New Frontier in Personalized Cancer Therapy: Mapping Molecular Changes
Kasaian, K., & Jones, S. J. M. (2011) · Future Oncology · doi:10.2217/fon.11.63 · Cited by 12
Pitfalls in molecular diagnostics
Sun, L., & Pfeifer, J. D. (2019) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2019.06.002 · Cited by 12
Efficacy of anti-HER2 drugs in the treatment of patients with HER2-mutated cancers: a systematic review and meta-analysis
Zheng, Y., Shen, G., Zhang, C.-R., Huo, X., Xin, Y., Fang, Q., Guan, Y., Zhao, F., Ren, D., Liu, Z., et al. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01072-7 · Cited by 13
“Even so, HER2 mutations are widely present in a variety of cancers, such as approximately 4, 1–8%, 1–3.8%, and 4–6% in breast, lung, colorectal, cervical cancers, respectively, and the highest percentage in bladder cancer, approximately 9–18% [1, 3, 7–12].”
BackgroundInfluential
A Comprehensive Review on the Role of Human Epidermal Growth Factor Receptor 2 (HER2) as a Biomarker in Extra-Mammary and Extra-Gastric Cancers
Amisha, F., Malik, P., Saluja, P., Gautam, N., Patel, T. H., Roy, A. M., Singh, S. R. K., & Malapati, S. J. (2023) · Onco · doi:10.3390/onco3020008 · Cited by 13
“In lung adenocarcinomas, HER2 mutations have been reported, especially in Asian patient population, female sex and light/non-smokers [59,60].”
Background
HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology
Nelson, E. L. (2014) · Clinical Investigation · doi:10.4155/cli.14.62 · Cited by 12
Cancer genomics guide clinical practice in personalized medicine
Lehmann‐Che, J., Poirot, B., Boyer, J.-C., & Evrard, A. (2017) · Therapies · doi:10.1016/j.therap.2016.09.015 · Cited by 14
Progress in Treatment of Non-Small Cell Lung Cancer Harboring HER2 Aberrations
Ni, J., & Zhang, L. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s312820 · Cited by 12
“epidermal growth factor receptor (ErbB) family, which includes EGFR (HER1/ ERBB1), HER3 (ERBB3) and HER4 (ERBB4).(9) The HER2 gene (also known as”
Background
Respiratory Tract and Mediastinum
French, C. A. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4462-6.00002-7 · Cited by 12
A comprehensive catalogue of functional genetic variations in the EGFR pathway: Protein–protein interaction analysis reveals novel genes and polymorphisms important for cancer research
Savas, S., Geraci, J., Jurišica, I., & Liu, G. (2009) · International Journal of Cancer · doi:10.1002/ijc.24535 · Cited by 12
Tyrosine kinase activating mutations in human malignancies: Implications for diagnostic pathology
Holden, J. A., Willmore‐Payne, C., & Layfield, L. J. (2008) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2008.03.010 · Cited by 12
Targeting novel and established therapies for non-small cell lung cancer
Spicer, J. F., Chowdhury, S., & Harper, P. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.09.001 · Cited by 11
Current concepts in the molecular genetics of pediatric brain tumors: implications for emerging therapies
Tamber, M. S., Bansal, K. K., Liang, M., Mainprize, T. G., Salhia, B., Northcott, P. A., Taylor, M. D., & Rutka, J. T. (2006) · Child s Nervous System · doi:10.1007/s00381-006-0187-3 · Cited by 12
MR-based radiomics predictive modelling of EGFR mutation and HER2 overexpression in metastatic brain adenocarcinoma: a two-centre study
Li, Y., Jin, Y., Wang, Y., Liu, W., Jia, W., & Wang, J. (2024) · Cancer Imaging · doi:10.1186/s40644-024-00709-4 · Cited by 11
Molecular Diagnostics in Non-Small Cell Lung Carcinoma
Sholl, L. M. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-3399564 · Cited by 11
HER2 Overexpression and Amplification in Feline Pulmonary Carcinoma
Muscatello, L. V., Oto, E. D., Dignazzi, M., Murphy, W. J., Porcellato, I., Maria, R. D., Raudsepp, T., Foschini, M. P., Sforna, M., Benazzi, C., et al. (2021) · Veterinary Pathology · doi:10.1177/0300985820988147 · Cited by 11
“87% to 36% of patients with non–small cell lung cancer, caused by gene amplification or mutations.(11,14,16,17) Therapeutic strategies are available for the targeted treatment of human HER2þ lung cancers using monoclonal antibodies.”
BackgroundResult
Acquired Substrate Preference for GAB1 Protein Bestows Transforming Activity to ERBB2 Kinase Lung Cancer Mutants
Fan, Y., Wong, L., Marino, M. P., Ou, W., Shen, Y., Wu, W. J., Wong, K., Reiser, J., & Johnson, G. R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.434217 · Cited by 11
“ERBB2 kinase mutations in the C- 4 region have been identified in non-small cell lung cancers (7, 8).”
Background
Direct resequencing of the completeERBB2coding sequence reveals an absence of activating mutations inERBB2amplified breast cancer
Zito, C. I., Riches, D., Kolmakova, J., Simons, J. F., Egholm, M., & Stern, D. F. (2008) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20566 · Cited by 11
Non–Small Cell Lung Cancer
Wagner, H. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1637-5.00042-0 · Cited by 12
On ubiquitin ligases and cancer
Beckmann, J. S., Maurer, F., Delorenzi, M., & Falquet, L. (2005) · Human Mutation · doi:10.1002/humu.20175 · Cited by 11
“Hence, these two groups of signaling pathways play an apparently equivalent role in cancer formation and represent primary targets for mutation detection—as has recently been illustrated for ERBB2 [Stephens et al., 2004]—and for the design of antitumor therapies.”
Background
Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation
Taja‐Chayeb, L., Candelaria, M., Brom, R., Trejo‐Becerril, C., Meza, F., & Dueñas‐González, A. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.05.015 · Cited by 11
Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions
Moasser, M. M. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1121 · Cited by 9
“Although the activation of HER2 through gene amplification and protein overexpression is by far the most commonly seen mode of HER2 activation in human cancers, there are also rare cases of HER2 activation through mutational alteration (108, 109).”
Background
A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells.
Yagui‐Beltrán, A., & Jablons, D. M. (2009) · PubMed · Cited by 10
The EGFR/ERBB Receptor Family
Pareja, F. G., Pines, G., & Yarden, Y. (2015) · Springer eBooks · doi:10.1007/978-3-319-11888-8_4 · Cited by 9
Advancing Personalized Cancer Medicine in Lung Cancer
MacConaill, L. E. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0244-sa · Cited by 10
MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumourigenesis
Lu, D., Nagelberg, A. L., Chow, J. L. M., Chen, Y. T., Michalchuk, Q., Somwar, R., & Lockwood, W. W. (2022) · Cancers · doi:10.3390/cancers14061378 · Cited by 10
“Tumours harbouring mutations in genes such as EGFR [1–3] and ERBB2 [4,5], or gene rearrangements involving ALK [6,7], RET [8], or ROS1 [9] are typically dependent on the oncogene for survival, with profound anti-tumour effects observed in response to the appropriate targeted therapy.”
Background
Novel Therapies Targeting Signaling Pathways in Lung Cancer
Yagui‐Beltrán, A., He, B., Raz, D. J., Kim, J. H., & Jablons, D. M. (2006) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2006.07.001 · Cited by 10
Expression genomics and drug development: Towards predictive pharmacology
Liu, E. T. (2005) · Briefings in Functional Genomics and Proteomics · doi:10.1093/bfgp/3.4.303 · Cited by 10
Antibody-drug conjugates in solid tumors: a new frontier
Jaime‐Casas, S., Barragán-Carrillo, R., & Tripathi, A. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001064 · Cited by 8
The effect of carbamazepine, a strong CYP3A inducer, on the pharmacokinetics of zongertinib in healthy male volunteers
Tian, X., Esmaeili, H. A., Minich, D., Seitz, F., Roessner, P. M., Wind, S., Grempler, R., Gan, G., Chan, T. S., Mahmoudi, M., et al. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.4641 · Cited by 9
Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development
Wijesinghe, P., & Bollig-Fischer, A. B. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_1 · Cited by 9
Amivantamab: A New Hope in Targeting Non-small Cell Lung Cancer
Chawla, P. A., Billowria, K., & Gupta, G. D. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220523145609 · Cited by 9
Nuclear export signal mutation of epidermal growth factor receptor enhances malignant phenotypes of cancer cells.
Nie, L., Wang, Y., Hsu, J.-M., Hou, J., Chu, Y., Chan, L.-C., Huo, L., Wei, Y., Deng, R., Tang, J., et al. (2023) · PubMed Central · Cited by 8
Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers
Yang, Z., Zou, J., Sun, C., Peng, F., & Peng, C. Y. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1165781 · Cited by 9
“In NSCLC, HER2 mutational activation occurs in approximately 5% of patients with NSCLC, including exon 20 insertions and pointmutations, both in the kinase domain (Stephens et al., 2004).”
Background
HER2 phosphorylation induced by TGF-β promotes mammary morphogenesis and breast cancer progression
Shi, Q., Huang, F., Wang, Y., Liu, H., Deng, H., & Chen, Y. (2024) · The Journal of Cell Biology · doi:10.1083/jcb.202307138 · Cited by 9
Molecular Therapeutic Advances in Personalized Therapy of Melanoma and Non-Small Cell Lung Cancer
Kelleher, F. C., Solomon, B., & McArthur, G. A. (2012) · Journal of Personalized Medicine · doi:10.3390/jpm2020035 · Cited by 9
Les thérapies ciblées dans les cancers bronchiques non à petites cellules en 2014
Leduc, C., & Besse, B. (2014) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2014.08.014 · Cited by 9
Predictive Factors for Response and for Resistance to Tyrosine Kinase Inhibitor Therapy in Lung Cancer
Cappuzzo, F. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000268634.17956.5e · Cited by 9
Analysis of genomic variation in lung adenocarcinoma patients revealed the critical role of PI3K complex
Deng, Z. M., Liu, L., Qiu, W. H., Zhang, Y. Q., Zhong, H., Liao, P., & Wu, Y. (2017) · PeerJ · doi:10.7717/peerj.3216 · Cited by 9
Membranous or Cytoplasmic HER2 Expression in Colorectal Carcinoma: Evaluation of Prognostic Value Using Both IHC & BDISH
Buhmeida, A. S., Assidi, M., Al-Maghrabi, J. A., Dallol, A., Sibiany, A., Al-Ahwal, M. S., Chaudhary, A., Abuzenadah, A. M., & Al-Qahtani, M. H. (2018) · Cancer Investigation · doi:10.1080/07357907.2018.1439054 · Cited by 9
“Some studies in lung cancer and other tumors explored this association thoroughly and concluded that HER2 mutations were not associated with HER2 amplification or overexpression (39,40).”
Background
Targeting ERBB Receptors in Cancer
Hynes, N. E. (2007) · Springer eBooks · doi:10.1007/978-3-540-31209-3_4 · Cited by 9
The efficacy of ado-trastuzumab emtansine in patients with ERBB2-aberrant non-small cell lung cancer: a systematic review
Huang, X. Y., Jin, R., Lou, L., Zhao, J., Xia, L., Zhao, J., Li, W., Xu, Z., & Xia, Y. (2020) · Translational Cancer Research · doi:10.21037/tcr-19-2759 · Cited by 8
“Recent literatures revealed that the frequency of ERBB2 gene mutation, gene amplification, protein overexpression in NSCLC were 1–4% (3-7), 2–5% (8-10) and 10–15% (11,12), respectively.”
Background
Untangling the KRAS mutated lung cancer subsets and its therapeutic implications
Kulshrestha, R., Kumar, P., Singh, A., Nupur, K., Spalgias, S., Mrigpuri, P., & Rajkumar (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00061-0 · Cited by 8
Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer
Claerhout, S., Lehnert, S., Borght, S. V., Spans, L., Dooms, C., Wauters, E., Vansteenkiste, J., Weynand, B., Deraedt, K., Bourgain, C., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.02.013 · Cited by 8
EGFR family heterodimers in cancer pathogenesis and treatment
Stern, H. M. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-356-1_2 · Cited by 8
HER2 transmembrane domain mutation: comprehensive characteristics and real-world evidence of treatment response in Chinese lung adenocarcinoma
Jia, Z., Xing, J., Li, J., Wang, W., Wang, Y., Song, Y., Yang, X., Xue, J., Ye, J., Li, B., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-107 · Cited by 7
Bioterapia: aplicaciones actuales y futuras en oncología
Prat, A., & Baselga, J. (2007) · Medicina Clínica · doi:10.1157/13107796 · Cited by 8
Molecular Biology of Lung Cancer
Wistuba, I. I., Liao, Z. X., & Milas, L. (2006) · Springer eBooks · doi:10.1007/3-540-31040-1_6 · Cited by 8
Oncogenomics Methods and ResourcesPreprint
Furney, S. J., Gundem, G., & López-Bigas, N. (2012) · Cold Spring Harbor Protocols · doi:10.1101/pdb.top069229 · Cited by 8
CAR-T for Lung Cancers: Challenges and Innovations
Trudu, L., Rovesti, G., Neri, G., Pugliese, G., Silingardi, M., Brini, L., Golinelli, G., Baschieri, M. C., Lallo, E., Guaitoli, G., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108711 · Cited by 8
Bayesian Networks Learning for Gene Expression Datasets
Gamberoni, G., Lamma, E., Riguzzi, F., Storari, S., & Volinia, S. (2005) · Lecture notes in computer science · doi:10.1007/11552253_11 · Cited by 7
Real-world therapeutic strategies and survival outcomes in advanced HER2-mutant non-small cell lung cancer
Sun, R.-L., Liao, P.-Y., Liao, Y.-T., Yeh, Y., Chiang, C., Chen, Y.-M., Hsu, K.-H., Tseng, J., Huang, H.-C., Shen, C., et al. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001212 · Cited by 7
Phosphorylation of Mutationally Introduced Tyrosine in the Activation Loop of HER2 Confers Gain-of-Function Activity
Hu, Z., Wan, X., Hao, R., Zhang, H., Li, L., Li, L., Xie, Q., Wang, P., Gao, Y., Chen, S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123623 · Cited by 7
“In addition to amplification, intragenic insertional mutations of HER2 are observed in 4% of lung cancers [5], and its kinase domain mutations are observed in 5% of gastric carcinomas, 2.”
Background
New Lung Cancer Panel for High-Throughput Targeted Resequencing
Kim, E., Lee, S., Park, J., Lee, K., Bhak, J., & Kim, B. C. (2014) · Genomics & Informatics · doi:10.5808/gi.2014.12.2.50 · Cited by 7
“ALK 29 5,153 98 98 99 [15] APC 15 8,674 98 99 100 [16] ATM 62 9,781 93 94 99 [3, 17] CDKN2A 4 1,028 0 64 75 [18] EGFR 30 4,178 99 98 97 [19] EML4 24 3,122 99 100 98 [15] EPHA3 17 3,122 99 99 99 [20] EPHA5 19 3,252 94 94 98 [3] ERBB2 27 4,038 94 93 93 [21] ERBB4 28 4,207 97 98 99 [3] FGFR4 16 2,643 92 88 91 [22] GNAS 1…”
Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor
Hu, Z., Hu, Y., Liu, X., Xi, R., Zhang, A., Liu, D., Xie, Q., & Chen, L. (2015) · Oncotarget · doi:10.18632/oncotarget.5221 · Cited by 6
3.13 Computational Methods Related to Molecular Structure and Reaction Chemistry of Biomaterials ☆
Farokhirad, S., Bradley, R. P., Sarkar, A., Shih, A., Telesco, S., Liu, Y., Venkatramani, R., Eckmann, D. M., AYYASWAMY, P. S., & Radhakrishnan, R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803581-8.10216-4 · Cited by 7
A significant response to a combination of trastuzumab and vinorelbine in HER2-negative metastatic breast cancer with HER2 V777L mutation
Lei, L., Ye, W.-W., Zheng, L., Huang, P., Shi, L., Huang, J. H., Zheng, Y., Chen, Z., Wang, X., & Wang, X. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s199931 · Cited by 7
Application of informatics in cancer research and clinical practice: Opportunities and challenges
Hong, N., Sun, G., Zuo, X., Chen, M., Liu, L., Wang, J., Feng, X., Shi, W., Gong, M., & Ma, P. (2022) · Cancer Innovation · doi:10.1002/cai2.9 · Cited by 7
Recent and new targets for small molecule anti-cancer agents
Ovaa, H., Kuijl, C. P., & Neefjes, J. (2009) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2010.01.001 · Cited by 7
Histotype in Non-Small Cell Lung Cancer Therapy and Staging: The Emerging Role of an Old and Underrated Factor
Rossi, G., Marchioni, A., Sartori, G., Longo, L., Piccinini, S., & Cavazza, A. (2007) · Current Respiratory Medicine Reviews · doi:10.2174/157339807779941820 · Cited by 7
“Again, never-smokers, femal gender and adenocarcinomas were significantly associated with these mutations [107, 108].”
Background
Caspase8 rs1035142 G>T polymorphism was associated with an increased risk of esophageal cancer in a Chinese population
Yin, J., Tang, W., Shao, A., Wang, L., Wang, X., Ding, G., Liu, C., Chen, Y., Chen, S., & Gu, H. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3052-6 · Cited by 7
Investigating Molecular Mechanisms of Activation and Mutation of the HER2 Receptor Tyrosine Kinase through Computational Modeling and Simulation.
Telesco, S., Shih, A., Liu, Y., & Radhakrishnan, R. (2011) · PubMed · Cited by 7
Molecular Biology of Lung Cancer and Future Perspectives for Screening
Tarro, G., Paolini, M., & Rossi, A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.85334 · Cited by 7
Epidermal growth factor receptor pathway inhibitors
Baselga, J. M. (2006) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2006.08.002 · Cited by 7
Targeted Sequencing of Taiwanese Breast Cancer with Risk Stratification by the Concurrent Genes Signature: A Feasibility Study
Huang, C.-S., Liu, C.-Y., Liu, C., Huang, C.-J., Chiu, J., Tseng, L., & Huang, C. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11070613 · Cited by 6
“The ERBB2 rs28933370 missense mutation was reported as being pathogenic/likely pathogenic from ovarian cancer with somatic allele origin, while neither ascertain criteria nor alternative allele frequency from 1000 Genomes or the Taiwan Biobank were provided [30,31].”
Background
Patient-Derived Tumoroid for the Prediction of Radiotherapy and Chemotherapy Responses in Non-Small-Cell Lung Cancer
Nounsi, A., Seitlinger, J., Ponté, C., Demiselle, J., Idoux‐Gillet, Y., Pencreach, E., Beau‐Faller, M., Lindner, V., Balloul, J., Quéméneur, É., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11071824 · Cited by 8
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy
Vari, S., Pilotto, S., Maugeri‐Saccà, M., Ciuffreda, L., Incani, U. C., Falcone, I., Curatolo, A. D., Ceribelli, A., Gelibter, A. J., Maria, R. D., et al. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.843523 · Cited by 6
“The most common mutation is an in-frame insertion within exon 20, resulting in increased HER2 kinase activity, enhanced signaling through downstream pathways, and increased survival, invasiveness and tumorigenicity [51-53].”
Background
Other signalization targets
Girard, N. (2013) · Targeted Oncology · doi:10.1007/s11523-012-0246-5 · Cited by 7
“Interestingly, HER2 mutations are present in 2 % of NSCLCs [30, 32].”
Background
Targeted therapies in non-small cell lung cancer
Kyle, F. J. (2008) · Cancer Imaging · doi:10.1102/1470-7330.2008.0027 · Cited by 6
“HER2 over expression occurs in only approximately 10% of patients with NSCLC, and activating mutations have been detected in approximately 4% of adenocarcinomas([34]).”
Background
System properties of ErbB receptor signaling for the understanding of cancer progression
Okada, M. (2006) · Molecular BioSystems · doi:10.1039/b612800a · Cited by 6
Sensitive methods for the detection of an insertion in exon 20 of the HER2 gene in the metastasis of non-small cell lung cancer to the central nervous system
Krawczyk, P. A., Nicoś, M., Powrózek, T., Mlak, R., Sawicki, M., Jarosz, B., Pająk, B., Kucharczyk, K., Stencel, D. M., Trojanowski, T., et al. (2013) · Oncology Letters · doi:10.3892/ol.2013.1495 · Cited by 6
Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer
Daoud, A., & Chu, Q. S.-C. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00222 · Cited by 6
“The most common HER-2 mutation is exon 20 in-frame deletion or insertion between codons 776–779 (44, 45), which occur in 1.”
Background
Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases
Koivu, M. K. A., Chakroborty, D., Tamirat, M. Z., Johnson, M. S., Kurppa, K. J., & Elenius, K. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0590 · Cited by 5
Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake
Toma, A. D., Russo, G. L., Signorelli, D., Pagani, F., Randon, G., Galli, G., Prelaj, A., Ferrara, R., Proto, C., Ganzinelli, M., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103299 · Cited by 6
HER2 as a Therapeutic Target in Ovarian Cancer
Lukas, C., Wang, Y., & Hampto, G. (2012) · InTech eBooks · doi:10.5772/29064 · Cited by 6
“For example, mutations in HER2 are adjacent to or overlap with the analogous structural region of EGFR in-frame deletions that are associated with some lung tumors (Stephens et al., 2004).”
Background
The place of targeted therapies in the management of non-small cell bronchial carcinoma
Rosell, R., Morán, T., Salazar, M., Méndez, P., de Aguirre, I., Ramírez, J. L., Isla, D., Cobo, M., Camps, C., López-Vivanco, G., et al. (2006) · Revue des Maladies Respiratoires · doi:10.1016/s0761-8425(06)72061-7 · Cited by 6
Surrogate Predictive Biomarkers for Response to Anti-EGFR Agents: State of the Art and Challenges
Cappuzzo, F., Toschi, L., Finocchiaro, G., Ligorio, C., & Santoro, A. (2007) · The International Journal of Biological Markers · doi:10.5301/jbm.2008.5699 · Cited by 7
Human Epidermal Growth Factor Receptor 2–Mutant Non–Small-Cell Lung Cancer: Continued Progress But Challenges Remain
Cooper, A. J., & Gainor, J. F. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02550 · Cited by 7
Unraveling the molecular-pathological characteristics and cellular complexity of the tumor immune microenvironment in metastatic non-small cell lung cancer
Bharadwaj, S., Mierzwicka, J. M., Vaňková, L., & Malý, P. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02410-w · Cited by 7

Authors: Stephens, P., Hunter, C., Bignell, G., Edkins, S., Davies, H., Teague, J., Stevens, C., O'Meara, S., Smith, R., Parker, A., Barthorpe, A., Blow, M., Brackenbury, L., Butler, A., Clarke, O., Cole, J., Dicks, E., Dike, A., Drozd, A., Edwards, K., Forbes, S., Foster, R., Gray, K., Greenman, C., Halliday, K., Hills, K., Kosmidou, V., Lugg, R., Menzies, A., Perry, J., Petty, R., Raine, K., Ratford, L., Shepherd, R., Small, A., Stephens, Y., Tofts, C., Varian, J., West, S., Widaa, S., Yates, A., Brasseur, F., Cooper, C. S., Flanagan, A. M., Knowles, M., Leung, S. Y., Louis, D. N., Looijenga, L. H. J., Malkowicz, B., Pierotti, M. A., Teh, B., Chenevix-Trench, G., Weber, B. L., Yuen, S. T., Harris, G., Goldstraw, P., Nicholson, A. G., Futreal, P. A., Wooster, R., & Stratton, M. R.
Affiliations: Wellcome Sanger Institute (GB)
Ludwig Cancer Research (BE)
Institute of Cancer Research (GB)
University College London (GB)
Cancer Research UK (GB)
Queen Mary Hospital (CN)
Massachusetts General Hospital (US)
Erasmus MC (NL)
University of Pennsylvania (US)
IFOM (IT)
Van Andel Institute (US)
Royal Brompton Hospital (GB)
Corresponding author: Futreal, P. Andrew
ORCID: Hunter, Chris
Edkins, Sarah
Davies, Helen
Teague, Jon
Blow, Matthew
Clarke, Oliver
Dicks, Ed
Foster, Rebecca
Gray, Kristian
Greenman, Chris
Raine, Keiran
Shepherd, Rebecca
Widaa, Sara
Yates, Andrew
Flanagan, Adrienne M.
Knowles, Margaret
Louis, David N.
Looijenga, Leendert H. J.
Pierotti, Marco A.
Teh, Bin
Yuen, Siu T.
Nicholson, Andrew G.
Futreal, P. Andrew
Stratton, Michael R.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2004-09
Volume: 431
Issue: 7008
Pages: 525-526
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/431525b
OpenAlex: W2049449785
Cited by: 802
References: 7
Citations by year: 2026: 14 · 2025: 25 · 2024: 19 · 2023: 20 · 2022: 31 · 2021: 41 · 2020: 26 · 2019: 26 · 2018: 34 · 2017: 30 · 2016: 20 · 2015: 45 · 2014: 61 · 2013: 46 · 2012: 40
FWCI: 48.46
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
UEA Digital Repository (University of East Anglia) (acceptedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
RePEc: Research Papers in Economics (submittedVersion)
DIAL (Catholic University of Leuven) (submittedVersion)
Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion)
UCL Discovery (University College London) (submittedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: ERBB2, HER2, c-erbB-2, kinase domain mutations, intragenic mutations, lung cancer, lung adenocarcinoma
MeSH terms: Gefitinib, Carcinoma, Non-Small-Cell Lung, DNA Mutational Analysis, Enzyme Activation, Humans, Lung Neoplasms, Models, Molecular, Mutation, Neoplasms, Quinazolines, Protein Structure, Tertiary, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Intragenic ERBB2 kinase mutations in tumours

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks